Department of Urology, University of Iowa Hospitals & Clinics, Iowa City, Iowa, USA.
J Endourol. 2023 Sep;37(9):978-985. doi: 10.1089/end.2023.0173. Epub 2023 Jul 31.
T3a renal masses include a diverse group of tumors that invade the perirenal and/or sinus fat, pelvicaliceal system, or renal vein. The majority of cT3a renal masses represent renal cell carcinoma (RCC) and have historically been treated with radical nephrectomy (RN) given their aggressive nature. With the adoption of minimally invasive approaches to renal surgery, the combination of improved observation, pneumoperitoneum, and robotic articulation has allowed urologists to consider partial nephrectomy (PN) for more complex tumors. Herein, we review the existing literature regarding robot-assisted PN (RAPN) and robot-assisted RN (RARN) in the management of T3a renal masses. A literature search was performed using PubMed for articles evaluating the role of RARN and RAPN for T3a renal masses. Search parameters were limited to English language studies. Applicable studies were abstracted and included in this narrative review. T3a RCC caused by renal sinus fat or venous involvement is associated with ∼50% lower cancer-specific survival than those with perinephric fat invasion alone. CT and MRI can both be used to stage cT3a tumors, however, MRI is more accurate when assessing venous involvement. Upstaging to pT3a RCC during RAPN does not confer a worse prognosis than pT3a tumors treated with RARN; however, patients who undergo RAPN for T3a RCC with venous involvement have relatively higher rates of recurrence and metastasis. Intraoperative tools including drop-in ultrasound, near-infrared fluorescence, and 3D virtual models improve the ability to perform RAPN for T3a tumors. In well-selected cases, warm ischemia times remain reasonable. cT3a renal masses represent a diverse group of tumors. Depending on substratification of cT3a, RARN or RAPN can be employed for treatment of such masses.
T3a 肾肿瘤包括一组侵袭肾周和/或窦脂肪、肾盂肾盏系统或肾静脉的不同肿瘤。大多数 cT3a 肾肿瘤代表肾细胞癌(RCC),由于其侵袭性,历史上一直采用根治性肾切除术(RN)治疗。随着微创肾手术方法的采用,改善观察、气腹和机器人关节运动的结合使泌尿科医生能够考虑对更复杂的肿瘤进行部分肾切除术(PN)。在此,我们回顾了关于 T3a 肾肿瘤管理中机器人辅助 PN(RAPN)和机器人辅助 RN(RARN)的现有文献。使用 PubMed 对评估 RARN 和 RAPN 对 T3a 肾肿瘤作用的文章进行了文献检索。搜索参数仅限于英语语言研究。适用的研究被提取并纳入本叙述性综述。 由肾窦脂肪或静脉受累引起的 T3a RCC 与单纯肾周脂肪侵犯的肿瘤相比,癌症特异性生存率降低约 50%。CT 和 MRI 均可用于分期 cT3a 肿瘤,但 MRI 在评估静脉受累时更准确。RAPN 期间升级为 pT3a RCC 并不比用 RARN 治疗的 pT3a 肿瘤预后更差;然而,接受 RAPN 治疗伴有静脉受累的 T3a RCC 的患者复发和转移的相对发生率较高。术中工具包括下入式超声、近红外荧光和 3D 虚拟模型,提高了对 T3a 肿瘤进行 RAPN 的能力。在选择良好的病例中,热缺血时间仍然合理。 cT3a 肾肿瘤代表一组不同的肿瘤。根据 cT3a 的分层,RARN 或 RAPN 可用于治疗此类肿瘤。